Prognostic factors of candidemia among nonneutropenic adults with total parenteral nutrition

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 6, 2011, Pages 461-466

  Tsai, Chen Chi ^a,b   Lay, Chorng Jang ^a,b   Wang, Chun Lung ^a,b   Lin, Mei Lin ^c,d   Yang, Su Pen ^c,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antifungal agent; Candidemia; Central venous catheter; Total parenteral nutrition

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ADULT; AGED; APACHE; ARTICLE; CANDIDA; CANDIDA GLABRATA; CANDIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; APACHE; CANDIDEMIA; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; PROGNOSIS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 83155180658     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.04.002     Document Type: Article

References (31)

1. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186.
2. Bross J., Talbot G.H., Maislin G., Hurwitz S., Strom B.L. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989, 87:614-620.
3. Cheng Y.R., Lin L.C., Young T.G., Liu C.E., Chen C.H., Tsay R.W. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 2006, 39:155-161.
4. Raad I., Hanna H., Boktour M., Girgawy E., Danawi H., Mardani M., et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004, 38:1119-1127.
5. Karlowicz M.G., Hashimoto L.N., Kelly R.E., Buescher E.S. Should central venous catheters be removed as soon as candidemia is detected in neonates?. Pediatrics 2000, 106:E63.
6. Viudes A., Pemán J., Cantón E., Ubeda P., López-Ribot J.L., Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002, 21:767-774.
7. Ambrosio G.B., Riva L.M., Zanchi P. Heart failure: problems of definition and clinical staging. Cardiology 1990, 35:707-712.
8. Vincent J.L., de Mendonça A., Cantraine F., Moreno R., Takala J., Suter P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
9. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Acute Dialysis Quality Initiative workgroup. Crit Care 2004, 8:R204-R212.
10. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
11. Cuenca-Estrella M., Lee-Yang W., Ciblak M.A., Arthington-Skaggs B.A., Mellado E., Warnock D.W., et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother 2002, 46:3644-3647.
12. de Montclos M., de Montclos H., Flandrois J.P. Comparative study of two systems for the determination of the sensitivity of yeasts to antifungal agents. Pathol Biol (Paris) 1992, 40:495-499.
13. Branchini M.L., Pfaller M.A., Rhine-Chalberg J., Frempong T., Isenberg H.D. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994, 32:452-456.
14. Shoham S., Levitz S.M. The immune response to fungal infections. Br J Haematol 2005, 129:569-582.
15. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
16. Miceli M.H., Bernardo S.M., Lee S.A. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 2009, 34:326-332.
17. Seidler M., Salvenmoser S., Müller F.M. Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. FEMS Yeast Res 2010, 10:492-495.
18. Mukherjee P.K., Long L., Kim H.G., Ghannoum M.A. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 2009, 33:149-153.
19. Lazzell A.L., Chaturvedi A.K., Pierce C.G., Prasad D., Uppuluri P., Lopez-Ribot J.L. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009, 64:567-570.
20. Colombo A.L., Guimarães T., Silva L.R., de Almeida Monfardini L.P., Cunha A.K., Rady P., et al. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007, 28:570-576.
21. Chen T.C., Chen Y.H., Tsai J.J., Peng C.F., Lu P.L., Chang K., et al. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan. J Microbiol Immunol Infect 2005, 38:200-210.
22. Bassetti M., Trecarichi E.M., Righi E., Sanguinetti M., Bisio F., Posteraro B., et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007, 58:325-331.
23. Bader M.S., Lai S.M., Kumar V., Hinthorn D. Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality. Scand J Infect Dis 2004, 36:860-864.
24. Clancy C.J., Staley B., Nguyen M.H. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother 2006, 50:3496-3498.
25. Adler A., Litmanovitz I., Regev R., Arnon S., Bauer S., Dolfin T. Breakthrough candida Infection in a preterm infant with congenital cutaneous Candida albicans infection. Am J Perinatol 2005, 22:169-172.
26. Cheung C., Guo Y., Gialanella P., Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006, 34:345-348.
27. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
28. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
29. Ben-Abraham R., Keller N., Teodorovitch N., Barzilai A., Harel R., Barzilay Z., et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004, 49:317-323.
30. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Serody J., Edwards J.E., et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995, 21:994-996.
31. Kataoka S., Kashiwa M., Saku K., Handa N., Akiyama H. Candidemia in non-neutropenic patients with an intravenous hyperalimentation catheter: good prognosis of Candida parapsilosis infection. Kansenshogaku Zasshi 1995, 69:969-974.